Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant ...
Hannah Koepsell was 11 years old when she was diagnosed with acute lymphoblastic leukemia (ALL), a cancer of the blood and bone marrow. Two years of chemotherapy followed, and in 2024, she rang the ...
For Wyman, that perspective has become part of what comes after his daughter's cancer journey. Emma is now a healthy ...
A reflection on shame, vulnerability and transformation, and how driftwood, the ocean and presence helped reshape one man's ...
In the phase 3 DESTINY-Lung04 trial, patients with HER2-mutant advanced non-small cell lung cancer treated with Enhertu went ...
Patients with early-stage EGFR-mutated non-small cell lung cancer (NSCLC) who took Tagrisso (osimertinib) for three years ...
A dedicated movement space can serve as a survivorship anchor, reinforcing identity, agency, and continuity through training ...
WCLC 2026 brought new lung cancer data on HER2-mutant, PD-L1-positive and EGFR exon 20 insertion-positive non-small cell lung ...
In this installment of Clinical Trial Corner, Dr. Dina Khalaf, a clinical associate professor in the University of Florida ...
Now, survivorship means that I have been through an experience that has forever shaped who I am, how I respond and what I ...
Dr. Dina Khalaf breaks down three clinical trials testing oral and targeted regimens for acute myeloid leukemia and myelodysplastic syndrome.
A peritoneal mesothelioma diagnosis at 21, five months postpartum, underscores the psychosocial burden of rare malignancy in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results